Several leading hematology/oncology societies and organizations have put forth value frameworks. Conceptually, these are approaches which are intended to combine measures of efficacy, toxicity, quality of life, and financial toxicity into a metric of value that can be used to influence treatment decisions. Our coverage of value frameworks will expand over time.
- 2015: American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options
- 2016: Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received PubMed
- 2018: A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)
- 2015 (Version 1.0): A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) PubMed
- 2017 (Version 1.1): ESMO-Magnitude of Clinical Benefit Scale version 1.1
ASCO Value Framework vs. ESMO-MCBS
- 2017: Do the American Society of Clinical Oncology Value Framework and the European Society of Medical Oncology Magnitude of Clinical Benefit Scale Measure the Same Construct of Clinical Benefit? PubMed
ASCO Value Framework vs. NCCN Evidence Blocks
- 2017: Value Frameworks for the Patient-Provider Interaction: A Comparison of the ASCO Value Framework Versus NCCN Evidence Blocks in Determining Value in Oncology PubMed
Frequently asked questions
|back to top|
Q: Do you plan to add value measures to HemOnc.org?
A: At some point in the future, we may add value measures to some regimens; however, given that these frameworks are recently introduced and undergoing frequent revision, we will continue to monitor their development, for now.